Drug Profile
C 103
Alternative Names: C-103; Orlistat reformulated - Callitas TherapeuticsLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Chelatexx
- Developer Callitas Therapeutics
- Class Anorectics; Lactones; Small molecules
- Mechanism of Action Lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Obesity in India (PO, Capsule)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Obesity in USA (PO, Capsule)
- 14 Aug 2018 Chemical structure information added